Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia
-
Published:2024-03
Issue:3
Volume:11
Page:e170-e171
-
ISSN:2352-3026
-
Container-title:The Lancet Haematology
-
language:en
-
Short-container-title:The Lancet Haematology
Reference7 articles.
1. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study;Bataller;Lancet Haematol,2024
2. Decitabine/cedazuridine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia in Canada;Yun;Curr Oncol,2023
3. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study;Garcia-Manero;Lancet Haematol,2024
4. Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US;Vachhani;Oncologist,2022
5. Integrating patient-centered factors in the risk assessment of MDS;Buckstein;Hematology Am Soc Hematol Educ Program,2019